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ABSTRACT 
Photodynamic therapy (PDT) is being investigated as an adjuvant treatment for 
malignant glioma, but the clinical results are unsatisfactory. One of the major 
problems is how to obtain high levels of photosensitizer within tumour tissue, to 
achieve maximal tumour cell photosensitization and tumour destruction. Selective 
uptake and retention of Haematoporphyrin Derivative (HpD) in tumour tissue, 
especially at the brain adjacent to tumour (BAT) region is an important factor in 
determining the efficacy of PDT. So the aim of this study is to investigate the HpD 
distribution in the tumour and BAT region using different administration methods 
---intravenous injection and intratumoural injection. 
Ten patients with malignant glioma entered this study. Five cases were injected 
with HpD intravenously at a dose of 5mg/kg body weight. Another five cases 
were injected with 10mg (2ml) HpD by stereotactic technique into the tumour 
centre. 24 hours later, the patients underwent craniotomy for tumour debulking. 
Biopsies of tumour and brain adjacent to tumour (BAT) were sent for analysis. 
In the intravenous injection group, the mean HpD level in the tumour centre is 
^ 
2.0±0.7^ig/g, lower than that at the BAT region (3.6±2.3^ig/g) (p>0.05) . 
However, in the intratumoural injection group, a significantly higher HpD level was 





Fluorescence microscopy showed that HpD was unevenly distributed at the 
periphery of blood vessels and stroma in the intravenous group. In the 
intratumoural injection group, bright and patchy distribution of HpD was also 
f 
evident in the tumour bulk. Intracellular uptake of HpD was observed at the BAT 
region of both groups. Further study with confocal laser scanning microscopy 
provided evidence that the photosensitizer was localized intracellularly. 
The finding of a high level of HpD at the BAT region by conventional intravenous 
administration is a promising result, since PDT can be expected to cause more 
tumour tissue destruction. However the distribution of HpD was variable and 
unpredictable, thus, HpD level measurement should be carried out before 
photoillumination. 
Intratumoural administration of HpD can achieve much a higher HpD level in the 
tumour centre. HpD also infiltrated into the periphery of the tumour. However the 
HpD level at the BAT region was low because of the irregular shape of the tumour 
mass. So if the tumour is deep-seated or recurrent, and the operation is difficult 
or impossible, it may be useful to combine direct intratumoural injection with 
interstitial PDT, that is to implant laser fibre inside the tumour mass. 
It is hoped, therefore, that the results of this study will answer the question of 
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CHAPTER 1. INTRODUCTION 
1. Current status in treatment of glioma 
Glioma make up between 40-50% of nervous system tumours (Thomas 1992). 
The relative incidence of various types of tumours in adults is approximately as 
follows: glioblastoma multiforme 50%; anaplastic astrocytoma 30%; 
oligodendrogliomas 6%; astrocytoma 5%; ependymal cell tumours 4 % (Harsh & 
Wilson 1990). The best available treatment regimen includes surgery, radiation 
therapy, and systemic chemotherapy, depending on histological diagnosis. The 
five-year survival rates in 1,980 patients (Mahaley et al. 1989) are as fol lows: 
pilocytic astrocytoma 77.7%; oligodendroglioma 60.6%; ependymoma 49 .5%; 
astrocytoma 32.5%; anaplastic astrocytoma 18.2%; glioblastoma multiforme 
5.5%. Even with multi-modalities treatment, the prognosis of malignant glioma is 
still unsatisfatory, and the median survival time is less than 1 year. 
Surgery of Gliomas 
Surgery remains a first necessary step in the treatment of gliomas and is the most 
effective way of removing a large amount of neoplastic cells. Debulking large 
tumours and those that cause mass effect can reduce intracranial pressure and 
lead to marked improvement in neurologically impaired patients (Harsh & Wilson 









Fankhauser 1991). Surgery potentiates the effects of radiotherapy, chemotherapy 
and immunotherapy and prolongs the survival of patients. 
CT and MRI imaging techniques can give the precise anatomical location of 
tumour. Intraoperative ultrasound can lead the surgeon to deep targets through 
overlying cortex, and is helpful in defining the margins of the tumour during radical 
excision (LeRoux et al. 1989). Operative microscopes often provide the surgeon 
with a better view of subtle changes in tissue colour, but the distinction between 
the tumour and the adjacent brain can sometimes be extremely difficult to see, 
especially deep in the white matter or in the basal ganglion. Tumour cells can be 
found beyond the area of low density, even 2 cm or more from the enhancing rim 
(Johnson, Hunt & Drayer 1989). A radical excision cannot remove the scattered 
nests of malignant cells extending into the surrounding brain, without endangering 
the functional capacity of the patient. 
A recent development has been the application of image-based stereotactic 
technique in the treatment of malignant gliomas (Kelly 1989). When the tumour is 
more centrally located, when it is small and likely to be missed at open surgery, or 
when the tumour margins are poorly demarcated by CT or MRI, it is better to 
subject the patient to a stereotactic biopsy (Apuzzo et al. 1987). This method can 
[ also be used to deliver interstitial radiation, microwave hyperthermia, or laser light 
for photodynamic therapy. The poor prognosis of malignant gliomas is often due 
to local recurrence of glioma. Tumour cells grow diffusely into functioning CNS 




surgery may cure patients wi th pilocytic astrocytoma, it has never cured patients 
wi th malignant glioma (Tribolet & Fankhauser 1 991). The management of residual 
tumour cells is a major factor in the treatment of glioma. 
Radiation Therapy of Gliomas 
- 1 
Radiation therapy is the major adjuvant treatment after surgical resection of most 
gliomas. The total dose is usually 50-55Gy for low grade gliomas and somewhat 
more in malignant glioma. The target volume may cover the oedematous zone 
surrounding the irregular contrast enhanced tumour area, to avoid serious post-
irradiation brain damage. The effectiveness of radiotherapy, although questioned 
for differentiated gliomas in younger age groups, is beyond doubt, and may 
prolong life in adults, though less so for malignant glioma (Morantz 1 987; Walker, 
Green & Byar 1980). In 621 patients wi th glioblastoma multiforme (GBM), Walker 
found that radiotherapy at 60Gy increased the median life span by 2.3 times in 
comparison to patients who did not receive radiotherapy. 
To achieve tumour destruction without damage to surrounding brain, interstitial 
radiotherapy techniques were developed. Stereotactic implantation of iodine-125 
seeds directly into the tumour (bachytherapy) has prolonged survival in patients 
with high-grade astrocytoma (Larson et al. 1990), but controversy remains as to 
the best radioactive sources for the brain, isoeffects, and tissue tolerance 
(Bernstein et al. 1981; Ostertag 1989). 
9 
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‘ Stereotactic irradiation techniques (radiosurgery) w i th multiple cobalt sources, or 
linear accelerator (Colombo, 1985), deliver high doses of radiation to the tumour 
while minimizing the exposure of adjacent normal brain. Experience wi th this 
method of treating glioma is limited (Coffey, Luusford & FIickinger 1991), and it is 
unlikely that it wil l be useful for large tumours. 
Chemotherapy for gliomas 
Evidence from numerous clinical trials confirms that chemotherapy, particularly 
wi th nitrosoureas or procarbazine, has a significant biological effect in glioma, 
producing modest increases in median survival and in the rate of long term 
survival. In adjuvant therapy immediately fol lowing surgery and radiotherapy for 
newly diagnosed cerebral glioma, BCNU significantly increases the survival rate of 
patients wi th malignant cerebral glioma by about 9% at 1 year and 3 .5% at 2 
years ( Stenning, Freedman & Bleehen 1987) 
Chemotherapy is based on the differential sensitivity of tumour cells to cytotoxic 
drugs compared with normal cells, and the ability of drugs to penetrate tumour 
tissue. In the tumour region, the Blood Brain Barrier (BBB) is defective or absent. It 
allows chemotherapeutic agents to act at the site of the tumour. Also most 
effective chemotherapeutic agents are highly lipid soluble. This property allows 
relatively free access to the entire central nervous system and permits the agents 
to reach not only the tumour mass, but also malignant cells located at a distance 
from the main mass。 
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However, at the periphery of a glioma, where tumour cells are lightly infiltrating 
normal brain, the capillary endothelial cells may maintain an effective BBB. 
Currently, chemotherapy has a weaker therapeutic effect in cerebral glioma than 
surgery or radiotherapy, and even the combination of all three modalities fails to 
effectively control malignant glioma (Eyre et al. 1983; Kornbith & Walker 1988). 
New Modalities 
The management of residual tumour cells is a critical factor in the treatment of 
glioma. Attempts have been made to differentiate tumour cells from their normal 
counterparts, particularly in the site of tumour invaded brain. This may be based 
on specific cell surface structure of tumour cells, unique metabolic property of 
tumour cells, or a host immune reaction toward tumour cells. At present, several 
modalities of treatment for brain tumour are under experimental clinical trials, 
I 
including photodynamic therapy, boron-neutron capture therapy, monoclonal 
antibody targeting therapy, adoptive immunotherapy and brachytherapy. But as 
yet, there have been no definite breakthroughs. 
Gene therapy is currently under investigation as an adjuvant treatment modality 
for malignant tumours. Recent research using rodent models of CNS gliomas 
indicates that a combination of gene transfer and drug treatment may be 
successful in killing tumour cells. Selective tumour cell killing is possible wi th the 
introduction of the herpes simplex virus (HSV)-thymidine kinase (TK) gene into 
cells, followed by treatment with antiviral drugs such as ganciclovir. The HSV-TK 
I 




analogs such as ganciclovir into "suicide nucleotides" that kill cells by inhibiting 
deoxyribonucleic acid synthesis ( Takamiya, Short & Moolten 1993). Using a 
mouse model, Culver et al (1992) put the virus into growing tumour cells by 
injecting packaging cells producing the TK-encoded virus into a tumour mass in 
mouse brain. After the treatment with ganciclovir, complete regression of tumour 
occurred in 11 out of 14 cases. Other DNA and RNA viruses such as adenoviruses 
and poxviruses are being studied for use in gene therapy ( Grunhaus & Horwitz 
1992). 
However, normal mammalian cells do not express the HSV-TK gene and are 
therefore resistant to ganciclovir cytotoxicity (Barba, Hardin & Ray 1993). The 
application of new molecular genetic techniques may allow us to control the 









2. Basic Principle of Photodynamic Therapy 
Photodynamic therapy is based on the principle that a photosensitive dye, after 
having been administered, can be selectively taken up and retained by malignant 
tissue, followed by treatment of the tissue wi th light of an appropriate wavelength 
to activate the sensitizer, and so cause selective destruction of the tumour. 
Photosensitizer 
A photosensitizer is a chemical that will absorb light energy of an appropriate 
wavelength, leading to a photosensitising effect, and ultimately causing tumour 
necrosis. Based on photochemical and photophysical properties, the sensitized 
molecule rises to an excited energy state once a photon is absorbed. The 
sensitizer can either decay back to ground state, wi th the emission of energy in 
the form of long-life fluorescence, or it can participate in a series of photochemical 
reactions. 
The most widely used photosensitizer so far is haematoporphyrin derivative (HpD). 
It is a complex of monomeric and oligomeric porphyrin (Berenbaum, Bonnet & 
Scourides 1982), and is a series of structurally related derivatives. 
Photosensitising effect of HpD 
When a photon is absorbed by a photosensitive molecule, a cytotoxic reaction can 
be triggered. Two types of reaction can be distinguished. In a type I reaction, a 
I sensitizer reacts directly with a celluar target which results in the production of 
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radicals. In a type II reaction energy is transfered to a ground state oxygen 
molecule, which results in singlet molecular oxygen. This is a very reactive 
product and reacts with many organic molecules (Weishaupt, Gomer & Dougherty 
1976; Moan, Peterson & Christensen 1979). Singlet oxygen is the most important 
cytotoxic agent. The type II reaction is the most important reaction and is the 
main mechanism of PDT. Since the duration of the singlet oxygen state is very 
short, it causes a local cytotoxic effect. The exact cellular targets of these excited 
intermediates are uncertain, although damage to the cell membrane (Bellnier & 
Dougherty 1982), mitochondria (Berns, Dahlman & Johnson 1982) and lysosome 
(Torinuki, Miura & Seiji 1980) has been reported. It seems that excited 
intermediates only cause cell death in the immediate vicinity where it was 
produced within 10 |im of its site of origin (Moan 1 984). 
A photosensitizer can only produce singlet oxygen if it absorbs light wi th greater 
energy than that required to excite oxygen to its singlet state. So the wavelength 
of light that produces a photodynamic reaction predominantly is in the visible part 
of the spectrum. Short wavelength light is absorbed very rapidly in tissue. As a 
result, it is longer wavelength (red) light that penetrates tissue best. To maximize 
tissue penetration, the ideal neurosurgical photosensitizer should strongly absorb 
the longest wavelength light possible. 
HpD has the maximum absorption peak at 400 nm, but has poor absorptive 
properties at the red end of the spectrum, and since red light has a deeper 
penetration in tissue, the appropriate wavelength used for PDT is 630nm. 
14 
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More recently, second-generation photosensitizers have been used in 
photodynamic therapy. Meso-tetra-hydroxyphenyl-chlorin (mTHPC) has a strong 
absorption at 652 nm, thus having higher efficiency than Photofrin ll_ The cellular 
uptake of the dye was observed by CLSM (Ma, Moan & Berg 1994). Another dye, 
albuminum-chloro-tetrasulfonated phthalocyanine (AIS4Pc) was evaluated in in 
vitro and in vivo studies. It has absorption peak at 675 nm, and has a higher 
tissue penetration depth, wi th less cutaneous phototoxicity ( Koshida, Hisazumi & 
Komatsu 1993). 
Mechanism of selectivity in PDT 
The mechanism for selective uptake and retention of PDT differs fundamentally 
between cerebral tumour and extracranial tumour. In extracranial tissues, tumours 
do not contain a very much greater concentration of photosensitizer than their 
host tissue (Tralau et al. 1 987). A differential in photosensitizer doses is not a 
predominant factor in photodynamic selectivity outside the CNS. When light is 
delivered interstitially via a fibre positioned in the centre of a tumour, then the 
tumour receives a greater light dose than surrounding normal tissue, which only 
receives attenuated light. 
The treatment of intracranial tumour is based on the mechanism of significant 
difference in photosensitizer concentration between tumour and normal tissue. A 
I 
number of studies showed that HpD was concentrated within glioma tissue to a 
degree that was greater than the normal brain (Wharen, Anderson & Laws 1 983; 
15 
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Boggan et al. 1984; Tralan et al. 1987; Steichen, Dashner & Martuza 1986; 
Kostron et al. 1986). Values ranged from 10:1 to 70:1 between tumour and 
normal brain for HpD, and maximal concentration of HpD in glioma within 4-24 
hours post intravenous injection (Boggan et al. 1984; Kaye, Morstyn & Ashcroft 
1985). Further studies dealing wi th determining intracellular localization of 
photosensitizer have shown that sensitizers mainly locate in mitochondria, 
lysosomes, microsomes, cytoplasm, and not in the nucleus (Woodburn et al_ 
1991; Moan et al. 1982; Berns, Dahlman & Johnson 1982; Singh et al. 1987). 
Mitochondria may be major targets In the cytotoxic process induced by PDT in 
glioma. 
Selective localization and the blood brain barrier 
After intravenous injection, HpD components in circulating blood are bound to 
albumin and also to low density and high density lipoprotein (LDL, HDL) 
(Kongshaug, Moan & Brown 1 989). The level of LDL receptors plays an important 
role in the distribution of HpD in the body (Kessel & Cheng 1 985). 
I 
Intracranial tumours possess a different mechanism in HpD uptake and 
retention.The blood brain barrier plays an important role in the selective 
localization of HpD in cerebral tumours. The BBB is composed of endothelial cells 
and their tight junctions of the cerebral vessels. It prevents HpD leaking from 
circulating blood. In brain tumours, impairment of the BBB causes a change in 
vascular permeability’ This change in permeability may vary considerably between 
tumours and between regions of tumour. Some tumour capillaries are fenestrated 
16 
and highly permeable, and some may maintain characteristics of the normal BBB. 
This has been demonstrated in various experimental tumours and human brain 
tumours (Groothuis 1982; Boggan et al. 1984; Kaye, Morstyn & Ashcroft 1985). 
In the rat 9L gliosarcoma brain tumour model (Boggan et al. 1984), HpD was not 
uniformly taken up by the tumour. Only 33-44% of the tumour area was 
fluorescent. Within the tumour there were areas of intense fluorescence adjacent 
to areas of minimal or no fluorescence. This suggested a globular patchy 
distribution of HpD. 
Yamada et al_ (1982) used quantitative autoradiographic technique to measure 
BBB permeability of glioma in rats. As the tumour grew, BBB permeability 
increased in the centre of the tumour, where the neovascularized vessel was 
partly disrupted. But the BBB was partly preserved at the periphery of the tumour 
and the BAT region. The heterogeneity of the BBB phenomenon may be a major 
obstacle to uptake of photosensitizers. 
To enhance photosensitizer concentration in tumour tissue, intratumoral injection 
I of photosensitizer has been investigated in cerebral tumour models. Kostron et al. 
(1986) attempted direct intraneoplastic injection into subcutaneous and 
intracranial tumours in the rat glioma model. The results indicated that 
intraneoplastic injection was superior to intraperitoneal injection for increasing 
tumour HpD concentration, and correlated with an increased cytotoxic effect. 






canine glioma model and showed intraneoplastic injection led to more efficient 
uptake of HpD, especially at the tumour periphery. Fluorescence microscopy 
confirmed the selective biodistribution of HpD fluorescence within the cytoplasm 
of tumour cells. 
In human glioma, Kostron et al. (1987) compared the results of three injection 
modalities (intravenous, intraarterial, intratumoral) in 14 patients wi th malignant 
brain tumours. After PDT, histological examination showed pronounced necrosis 
and disaggregation of the tumour cells, while the vessels' endothelia were more or 
less intact. Intravenous and intraarterial injection demonstrated a predominantly 
vascular and cellular effect. 
Cytotoxic effect of PDT 
Direct kill of tumour cells by PDT has been demonstrated in vitro (Moan et al. 
1982; Hamilton et al. 1986), but the tumour cell kill in vivo may be different. The 
fundamental mechanism of whether tumour destruction is a result of actual PDT 
phototoxic effects on the tumour cell, or the tumour microvasculature remain 
incompletely understood. Many reports indicated the latter is the main destructive 
mechanism in the case of intravenous administration of photosensitizer. Nelson et 
al. (1988) found destruction of collagen fibres and other connective tissue 
elements located in the subendothelial zone of the tumour capillary wall in tumour 
bearing mice. Further observation in the C6 rat glioma model showed tumour 
blood vessels were primarily damaged in PDT, with the tumour subsequently 
undergoing ischemic change {Kaye & Morstyn 1987). 
18 
r 
.• L) / 
• y S 
The question of whether tumour, vascular, stromal or cellular damage is the 
dominant mechanism of PDT has yet to be resolved. MutlipIe factors may be 
responsible for the efficacy of PDT。 
PDT on norma! brain 
Laboratory studies on the effect of PDT treatment on normal brain, suggest that 
there may be a threshold of PDT treatment, below which brain is spared damage. 
Kaye et al (1987) found few or no lesions present wi th photosensitizer doses of 
<200J/cm^ , 24 hours following injection of photosensitizer in normal rat brain. 
However, other investigations have noted significant damage to normal brain 
produced following PDT treatment. 
Cheng et al (1984) investigated the relationship between laser energy, HpD doses 
and damage to normal brain tissue. Normal rats received HpD 5 to 10 mg/Kg of 
body weight, followed by laser exposure at various doses or were exposed to a 
fixed laser dose after the administration of HpD, 2.5-20mg/Kg. After PDT, the 
extent of brain damage correlated with increases in the dose of both the laser and 
HpD. 
Futher study was conducted to clarify the degree of damage and the temporal 
relationship between histological changes, vascular permeability changes ahd 
oedema present following PDT treatment of normal rat brain (Dereski, Chopp & 
Chen 1989). Histopathology revealed a large cerebral infarct following treatment, 
\ 
Evans blue extravasation indicated vascular permeability was increased, and 
19 
specific gravity measurement indicated a significant amount of edema present at 
24 hours post treatment. Berenbaum et al (1986) also did a histological study on 
brain damage induced by PDT. It showed an early breakdown of BBB and damage 
to endothelial cells, indicating that vascular damage is the main factor in the 
destruction of normal cerebral tissue. 
20 
3. Photodynamic therapy in clinical neurosurgery 
Clinical PDT has been conducted for more than 10 years. It has been used for the 
treatment of several types of tumour, including tumours of the oesophagus, 
bladder, skin, and lung. For different parts of the body and different kinds of 
tumour, the response to the treatment varies considerably. 
PDT has been shown to be especially useful for the control of local disease, 
thereby providing a rationale for its further investigation in the treatment of 
infiltrating cerebral tumours. A number of investigators made PDT an adjuvant 
treatment of human malignant brain tumour (Perria et al. 1 980; Laws et al. 1981; 
Wharen, Anderson & Laws 1983; Kaye, Morstyn & Brownbill 1987; Kostron et al. 
1986; Muller & Wilson 1985; Muller & Wilson 1987; Perria et ai. 1988; Powers et 
al. 1991; Origitano & Reichman 1993). 
Perria and colleagues (1980) reported their first clinical applications of PDT in 
human glioma, which demonstrated that PDT could be applied to patients 
relatively safely without undue side effects except that of cutaneous 
hypersensitivity to light. Since then more than 270 cases of intracranial 
neoplasms have been treated with PDT using a variety of treatment protocols 
(Origitano & Reichman 1993). 
I During surgery the tumour was resected as radically as possible, then the tumour 
bed was irradiated. The light was delivered through an optical fibre into the centre 
21 
of the tumour cavity. The temperature of the tumour cavity was kept below 37.5 
°C by irrigation with either normal saline or 0 .5% lntralipid. Because light dose to 
the surface of an irregular sphere was not uniform, precise calculations of light 
dose were not possible with this method. Muller and Wilson (1990) have 
approached this problem more scientifically by devising an inflatable balloon 
system filled with 0.5% lntralipid which can be inflated to fill a tumour cavity. 
This has the advantage of converting an irregular cavity into a sphere which 
allows for more precise, uniform light distribution. 
The light source for clinical application of PDT should be a sufficiently powerful 
source of monochromatic light that matches the absorption peak of 
photosensitizer being used. Initially, non-laser sources such as the xenon lamp 
were used (Wharren, Anderson & Laws 1 983). The most commonly used light 
sources nowadays, for both experimental and clinical work, are lasers, including 
gold vapour laser, argon laser and copper vapour laser. Gold vapour laser produces 
an output wavelength at 628nm, and argon laser produces two main output 
I wavelength of 488nm and 514.5nm. None of the commercially available lasers 
I produces a sufficiently powerful output to optimize selective glioma PDT. 
j The optical penetration depth is very important, since it determines whether the 
light, which is sufficient for excitation of a photosensitizer, can reach the 
periphery of malignant tissue. The optical penetration depth is in brain tissue for 
red light which is used in combination with HpD, is 2.5mm in malignant glioma 
tissue. (Muller & Wilson 1987; Eggert & Biazek 1987), Other studies have shown 
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a selective tumour destruction of up to 1 cm with HpD and red light in the rat 
model (Kaye & Morstyn 1987). The limited light penetration depth may be 
insufficient to cover the irregular shape of the tumour remanant, and it is difficult 
for the light to reach neoplastic cells that infiltrate one to two beyond a solid 
tumour mass. 
In order to treat unresectable or residual tumours, intratumoral PDT was 
introduced by Laws et al. (1981). This method of light delivery, placing a laser 
fibre in the centre of a tumour, was feasible and safe. Due to the limitations of 
light penetration in brain, multiple fibre insertions would be required to treat 
tumours larger than a few cubic millimeters. Origitano & Reichman (1993) 
developed an image-based computer assisted treatment planning protocol to treat 
15 patients with recurrent malignant gliomas. Three to eighteen interstitial fibre 
probes were placed through tumour access catheters into the tumour tissue. This 
computer-assisted technique provides an accurate method of defining optic fibre 
I placement geometry for interstitial photoillumination. This multiple fibre placement 
helps to accomplish the photoillumination at the margin of tumour mass. Although 
i patients tolerated it well, the outcome was unsatisfactory. The recurrence tended 
to occur outside the effective light treatment volumes. Therefore the use of PDT 
as primary treatment for unresectable tumours would only be possible if the 
method could first be shown to be effective as an adjuvant therapy for resectable 
tumours. At the present time, other forms of interstitial therapy, such as 
1 brachytherapy and hyperthermia, are likely to be more effective as their effects 
penetrate tissue further (Winter et al. 1 985; Gutin et al. 1 984)。 
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To enhance photosensitizer concentration in tumour tissue, intratumoural injection 
of photosensitizer has been investigated in cerebral tumour models (Boggan et al. 
1985; Kaye, Morstyn & Ashcroft 1985). Possible advantages of intratumoural 
administration include: A higher concentration of photosensitizer in tumour than in 
the surrounding normal tissue, circumventing the BBB in parts of the tumour 
where the BBB is intact, wi th a higher concentration of photosensitizer in the 
infiltrating parts of the tumour, increasing selective tumour destruction, and less 
photosensitization of the skin. Kostron et al. (1987) demonstrated that 
intratumoural injection is feasible and tolerated well by patients. This method acts 
mainly against the tumour cells and is not mediated by coagulation of the vessels. 
Side effects of PDT 
Although PDT is relatively safe in clinical trials, Rounds et al. (1982) first drew 
attention to the fact that normal brain could be damaged by PDT. However, the 
major problem in clinical PDT is the photosensitivity of the skin (Dougherty, 
Cooper & Mang 1 990). Using 5mg/Kg HpD intravenously, the average length of 
time that patients have to remain out of the daylight is 4 weeks (Kaye, Morstyn & 
Brownbill 1987). Muller and Wilson (1987) reported increased cerebral oedema 
after PDT, and the mean ICP was significantly higher in the PDT group than in the 
control group. Powers et al. (1991) observed that ail patients treated with 
intratumoural PDT developed cerebral oedema around the tumour; symptoms 
j related to oedema generally resolved spontaneously within one week of PDT. 
24 
In summary, photodynamic therapy has been accepted as an adjuvant therapy 
with acceptable risk in the treatment of glioma. All studies showed a 
photodynamic effect on tumours treated. However, the result of initial trials is 
unsatisfactory. This may be due to: most treated tumours were high grade glioma 
or recurrent tumour; optimal treatment parameters remain elusive; light 
penetration is limited; the number of patients is small. Thus it is not possible to 
draw any definite conclusion as to the efficacy ot PDT of glioma (Noske, Wolbers 







4. The aims of the study 
One of the major problems in the optimization of PDT for the treatment of glioma 
is how to obtain spatial distribution of photosensitizer within tumour and 
surrounding brain to obtain maximal tumour cell photosensitization and tumour kill. 
i 
The BAT (brain adjacent to tumour) is an important region since infiltrative 
malignant cells are more peripheral and may have shorter cell-cycle times than 
those of the main tumour mass, and neovascularization of this region may have 
normal capillary permeability. The regional variations in the tumour capillary bed 
can lead to non-uniform photosensitizer delivery after conventional intravenous 
I administration, and limit the effectiveness of PDT. 
In order to achieve higher HpD concentration in tumour tissue, direct intratumoral 
injection has been adopted in human glioma. So the aim of this study is to look at 
1 an alternative administration method - stereotactic intratumoral injection (IT) of 
HpD, to compare the distribution of photosensitizer in the tumour and brain 
adjacent to tumour (BAT) after IT and IV injection, and to investigate which 
method may be more effective for photosensitization of the infiltrated tumour, 
especially BAT. As BAT often contains intact BBB, and accounts for tumour 
recurrence after surgery, it will be the region where high photosensitizer 
concentration is desired. 
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The second purpose of this study to increase understanding of the selective 
uptake of HpD within the glioma cells or stroma. Whether stromal or cellular 
damage is the underlying dominant mechanism of PDT is controversial, but the 
precise location of photosensitizer is important. The proximity of photosensitizer 
to target cells will determine the efficacy of PDT. 
Two groups of patients entered this study (intravenous HpD injection, intratumoral 
HpD injection). 24 hours after administration of HpD, the patients underwent 
craniotomy. Biopsy specimens of tumour and BAT tissue were obtained during 
surgery. The biopsy specimens were used to analyse the HpD level of different 
regions of the tumour. The specimens were also examined with fluorescence 
microscope and confocal laser scanning microscope. Alternative histological 
sections were stained using conventional procedures. 
Fluorescence microscopy is the most direct method of determining intracellular 
localization of photosensitizer. Recently, confocal laser scanning microscope 
(CLSM) has been introduced to show intracellular localization of fluorescence. In 
this study, it was used to show HpD localization in BAT region. 
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CHAPTER 2. MATERIALS AND METHODS 
1. Patient population 
Ten patients aged from 34 to 74, mean age 50.3, of which 8 were male and 2 
female, were selected for this study. 7 patients had previously undergone surgery 
and all had been treated by radiation therapy. Table 1 summarizes the clinical 
features of these 10 cases. 
Patient selection was based on PDT having been carried out for the treatment of 
maligent glioma, especially those cases where conventional therapy had failed. 
Like most previous clinical PDT studies, we selected 7 cases of recurrent 
malignant glioma into this study. Their definite histological diagnoses had been 
obtained before administration of photosensitizer. 
I 
Ten patients with clinical and histological diagnosis of malignant glioma were 
j divided into 2 groups. 
Group A: conventional intravenous HpD administration (2 cases were recurrent 
tumours, 3 cases were primary tumours) 
i Group B: direct intratumoural HpD injection (ail cases were recurrent tumour) 
u ;i ‘ i 
i ； 
ii 
|i 2. Photosensitizer 
i 




The photosensitizer Hematoporphyrin Derivative (HpD) was obtained from 
Pharmacy Department, Queen Elizabeth Hospital ( Woodville, South Australia ). 
3. Administration of HpD 
In Group A, the HpD was injected intravenously 24 hours before operation at a 
dose of 5 mg/Kg body weight for 1 5-20 minutes. The patients were shielded from 
direct sunlight and intense indoor light for 4 weeks after administration of the 
drug. 
In Group B, all patients had recurrent tumours; 3 patients had no bone flap. Prior 
to direct intratumoral injection, CT or MRI was done to define the central region of 
tumour bulk (Fig 1). Then 2 ml (10 mg) HpD was injected into the tumour centre. 
The injection needle passed through the burr-hole into the tumour bulk. The 
. I ‘ i 
penetration depth of the needle was guided by stereotactic technique. After HpD 丨 
injection, patients were observed for any unexpected complications. 
24 hours after administration of HpD, the patient underwent general anesthesia 
and craniotomy for tumour debulking without adjuvant photoradiation therapy. 
！ Tumour localization and tumour biopsies were carried out via visual detection, and 
|i further aided by intraoperative ultrasound (Fig 2). In 8 cases, tumour debulking f| 
[| was done. Tumour tissue at the peripheral area of tumour bulk (proliferative 
[I ii 




normal brain at the cortex were also biopsied. In other 2 cases, tumour biopsy 
was done. 
In all patients, brain adjacent to tumour (BAT) were biopsied. BAT is the 
peritumoural oedematous brain, and the area between the region of apparent 
tumour tissue and normal brain (Fig 3). The brain adjacent to tumour region 
histologically showed infiltrating tumour cell in oedematous brain, but 
macroscopically appeared to be outside the tumour mass (Levin 1 975). In each 
region of tumour tissue or brain adjacent to tumour region, at least 3 samples 
were taken, they were collected for HpD quantitation, fluorescence microscope 
examination and confocal laser scanning microscope examination separately . 
All tumour samples were stored at -70°C immediately after biopsy and wrapped in 
] 
aluminium foil before analysis to minimize the potential of photobleaching of HpD. | 
4. Measurement of HpD 
Uptake of HpD into brain tissue was measured by previously published method 
(Kessel & Cheng 1985). 
A preweighted amount (30-60 mg) of tissue was suspended in 6 ml of 50 mM 
HEPES-10 mM CTAB, pH= 7.4, and homogenized for 30 seconds in a 
Homogenizer (PCU). 
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Triplicate 2 ml aliquots were removed, and each was mixed wi th 5 ml of a 
chloroform-methanol mixture (1:1, v/v ), thoroughly vortexed and centrifuged for 
5 minutes at 2000xg at room temperature in an IEC DPR-6000 centrifuge. The 
upper phase and a layer of cell debris at the interface between upper and lower 
phases were discarded, and then the lower phase was collected. 
All extracted porphyrins were present in the lower phase, with no porphyrins 
detectable in the upper phase and in the debris layer after re-extraction. The 
"chloroform-rich" lower phase was then evaporated to dryness under a stream of 
N2 gas, and the resulting residue was suspended in 1 ml of 0.5 M HCI and 
heated to 100。C for 30 minutes in sealed tubes. This hydrolysis step enhanced 
fluorescent yields. After being cooled to room temperature, the hydrolysates were 
I 
i. 
neutralized with 1 M NaOH, and then brought to a final volume of 2.5 ml with | 




The absorbance of these solutions at 400 nm was then determined using a Gilford 
spectrophotometer (Gilford instrument laboratories Inc., Oberlin, Ohio, USA) 
relative to a control blank. Those solutions with higher absorbance values were 
diluted with human tonicity phosphate-buffered saline, 100 mM CTAB, pH = 7.0, 
such that their final absorbance was equal to 0.15 absorbance unit in a 10-mm 
path length cell. This dilution step overcame the problem of concentration 
dependent quenching of the fluorescence emission by either the extracted 
porphyrin or haemoglobin that was coextracted with HpD from the tissue samples. 
A standard curve of HpD coextracted 5n the presence of added haemolyzate 
I 
i ‘ 31 
« 
A 
showed that haemoglobin neither enhanced nor quenched the fluorescence, 
provided the absorbance measured at 400nm in a 10 mm light path was below 




1 Fluorescence of the hydrolysate was determined using a fluorescence 
j 
I 
spectrophotometer (HITACHI model 650-40). The excitation wavelength was 400 
nm and the emission spectra were monitored at 625nm. The total porphyrin in 
each hydrolysate was determined relative to a standard curve of known amounts 
I 
of HpD prepared by this procedure. Before measurement of the standard curve of 
I 
HpD fluorescence, the absorbance of all samples at 400nm was determined. I ‘ 
1 i 
i • 
Those with absorbance greater than 0.15 in a 10mm light path were diluted such 
that the final absorbance was equal to 0.15, and the dilution factor was 
considered in all calculations. ' .: i 
； ! ' • 
. >! 
;i 丨  
A total of three aliquots of each tissue or tumour homogenate was assayed using ^ 
i . 丨‘ 
this procedure, and the porphyrin level in the sample was expressed as 




5. Fluorescence microscopic examination 
M 
ij 
i-, [； L.! f; 
All samples of tumour tissue and BAT region were examined. Tissue samples were 
ii 
taken from the same region as that for HpD quantitation. They were immersed in 
ii 
! liquid nitrogen immediately after excision, and mounted in OCT median, then 
stored at -70°C until examined. A series of sections were cut with a cryostat for 
S 32 
each tissue block, sections of 5 p<m thick were cut and mounted on clear glass 
slides without adhesive. The frozen sections were examined with fluorescence 
microscope (Leitz, PIOEMOPAK 2.5 fluorescence vertical illuminator) immediately. 
The microscope was equipped with filter Block G wi th excitation BP 350-460 and 
suppression LP 51 5 filter. Alternative sections were stained wi th haematoxylin-
eosin for light microscope identification of tissue structures. Photomicrographs 
were taken with colour Kodak film. 
- :i 
h 
6. Confocal laser scanning microscopic examination 
Two cases from the intravenous injection group and two cases from the 
|J 
I* 
intratumoural injection group were examined with this method. Tissue samples 
were taken from the same region as that for HpD quantitation and flourescence ! 
i 




specimens in the central and BAT regions were removed and placed in OCT | 
i 
Tissue-Tek embedding compound and then stored an -70 C until examined. A 
series of 20 ^im thick sections was cut. Unfixed and unstained cryrosections of 
I tumour and BAT were then taken and placed on glass slides and sealed with a 
glass coverslip. The slides were then kept in the dark to minimize photobleaching 
of HpD until analyzed on the confocal microscope. The HpD fluorescence was 
then detected by using Ultima confocal laser scanning microscope (Meridian 
Instruments, lnc 2310 Science Parkway Okemos, Michigan USA ), with excitation 














































































































































































































































































































































































































































































































































Fig 1 • CT scan showing right frontal recurrent anaplastic astrocytoma, 
(stereotactic intratumoural injection group ) 
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Fig 2_ Tumour tissue biopsy carried out under the guidance of intraoperative 
ultrasound. 
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Fig 3. A model of GBM shows tissue biopsies were taken from the peripheral 
area of tumour bulk ⑶，brain adjacent to tumour (BAT) region (4o and in some 
cases, the normal brain (=^). 
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CHAPTER 3. RESULTS 
The characteristics of the patients are summarized in Table 1. Five patients 
received HpD via intravenous administration. The other five patients received 
HpD via stereotactic intratumoral injection. None of them had photoradiation 
during surgery. In the intravenous HpD administration group, all patients were 
shielded from direct sunlight for 4 weeks.There were no adverse systemic 
!' 
reactions to the administration of HpD in both groups. Blood investigations f 
丨‘ 
following surgery indicated no evidence of haematological, hepatic or renal 
I 
toxicity from the therapy. None of the patients developed phototoxic skin burns. 
i j' 
I One patient died due to postoperative intracerebral haemorrhage. 丨： 
； ！“ 
I -'i 
j • . 
！ 丨丨 
1. HpD measurement 丨 
； I 、 
“； • ) 
‘ • I , 
I 
The results of the HpD uptake measurement are detailed in Table 2. The HpD I" 
丨产 
level in the sample was expressed as micrograms of porphyrin/ gram of tissue or ^ 
tumour wet weight, the mean HpD level in two groups was expressed as 
i 
mean±1SD ^ig/g respectively (Table 3). Fig 1 compares the HpD level in the 
tumour centre and BAT regions of both groups. 
In the intravenous HpD administration group, the mean HpD level is 2.0±0.7|ag/g 
in tumour bulk, 3.6±2.3j^g/g in brain adjacent to the tumour region {BAT). The 
HpD uptake into the BAT was greater than the uptake into the tumour bulk in 3 
； ； ； 
cases. Although the mean HpD level in BAT is higher than that in the tumour 
1 38 
bulk, there was no significant difference using an unpaired two tailed student's t 
test method, (p>0.05) 
In the intratumoral injection group, the mean HpD level was 4.7±3.2j ig/g In the 
tumour bulk, and 1.4i0.4| ig/g in brain adjacent to tumour (BAT). The HpD level 
in the tumour bulk was higher than BAT in all cases. There was significant 
difference in HpD level between these two regions, (p<0.05) 
1 
Although the mean HpD level of the tumour bulk was higher in the intratumoral 
j 
injection group than that in the intravenous injection group (4.7±3.2 vs 2.0±0.7 I 
^g/g)/ statistical analysis of these data using an unpaired two-tailed student's t 丨: 
.1 
M 
test method showed that there was no significant difference between these two 
‘ i 
, 、 
groups (p>0.05) . j 
丨 .“ 
I li 
\ \ • k 丨 ：f 
There were 5 cases where it was possible to obtain some normal brain biopsy ； 
丨 ：l 
during the approach; the HpD levels in normal brain were 0.2-0.6^ig/g in the 
I intravenous injection group and 0.3-0.9^ig/g in intratumoural injection group 
(Table 2). 
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2. Fluorescence microscope examination 
Selective distribution of fluorescence within tumour tissue following intravenous 
and intratumoural injection was observed by fluorescence microscopy. 
In the intravenous HpD administration group, fluorescence microscopy of these 
five cases showed that bright dots of fluorescence were located within the 
) ' ^ 
！ 1 
tumour tissue. HpD was shown as fluorescence. Within the tumour, fluorescence I: 
•1^  
distribution was uneven or patchy. There were areas of minimal or no ) 
't! ：： 
fluorescence. Fig 5 shows that the tumour centre consisted of poorly 
_ L 
differentiated pleomorphic glial cells. Tumour necrosis could also be seen. In the 〔 
. r 
alternative section of the same tumour tissue under fluorescence microscopy, the 
.'! 
necrotic area showed a lack of HpD fluorescence (Fig 6). On the other hand, with ) 
parallel examination of HE stained serial tissue section, there was more intense f i^  
V 
If 
fluorescence at the periphery of blood vessels in the BAT region (Fig 7, 8, 9, 
:f 
10). Normal brain from two cases was also examined; little fluorescence could ^ 
be detected. 
In the intratumoural HpD injection group, fluorescence of various intensities was 
observed throughout the cryostat sections of the tumour centre by fluorescence 
microscopy. Bright and patchy distribution of fluorescence could be detected at 
the injection site. (Fig 11, 12) Since the HpD infiltrated around the injection site, 
HpD uptake into cytoplasm could also be seen in tumour crytostat sections. 
Bright dots of fluorescence representing droplets of concentrated HpD were 
40 
located in the cytoplasm of tumour cells. In one case of GBM, tumour cells at the 
BAT region showed intracellular uptake of photosensitizer (Fig 13,14). Little 
fluorescence could be found in normal brain in 3 cases of this group. 
3. Confocal laser scanning microscope (CLSM) examination 
The HpD quantification indicates the selectivity of uptake of HpD into glioma, but 
|i^  
1, 
does not indicate the exact sites of localization. CLSM was used to define the |! ;, 
localization of HpD. Two cases for each group were studied with CLSM. The ) ii' I > 
micrographs show punctate fluorescence throughout the tumour tissue, some 丨 
I；', 
l|:, 
fluorescence localized within the cytoplasm and minimal uptake into the nucleus. : 
,t 
HpD can be detected intracellularly in BAT region in both groups. The 
'I 
'i 
micrographs (Fig 15) by confocal laser scanning microscopy (CLSM) showed 丨 
fluorescence located within the cell. But exact subcellular localization of HpD f k: V ! r 
could not be confirmed by CLSM alone. No fluorescence could be detected in 
I 
normal brain. • 
41 
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Table 2. HpD uptake into tumour and brain tissue 
Patient Pathology HpD level (^g of HpD/ g of tissue weight) 
number Tumour BAT Brain 
1 GBM l 0 5^ 
2 AA 12 0.8 
3 AA L6 4,2 
4 GBM 2 . 2 5.9 0.2 |^  
_5 GBM ^ 1_^  0.9 !| 
6 High grade oligo-astrocytoma 3.1 1.0 [；^ 
7 High grade oligodendroglioma 10.3 2.0 p 
8 AA 4.2 1.3 0.9 : 
9 GBM 2,6 1.1 0.7 丨 10 AA 3.5 1.4 0.3 
^ ^ - ^ ^ - • — - • - ^ ^ ^ ^ ^ — • ^ ^ ^ ^ ^ ^ — - - - ~ ^ ^ ^ — — - - — — ^ ^ ^ ^ ^ — - ' ^ ^ ^ ^ — - ^ ^ ^ ^ ^ ^ — — ^ ^ ^ ^ ^ ^ — ^ ^ — ^ ^ _ ^ _ ^ ^ — ^ ^ _ ^ _ _ ^ _ ^ ^ _ ^ _ ^ _ _ ^ ^ _ ^ ^ ^ _ ^ _ ^ _ (w 
I • 
Kt 
AA anaplastic astrocytoma � 







Table 3. Mean HpD levels in tumour center and BAT region* 
Brain tumour BAT 
Intravenous HpD 5mg/ Kg 2.0+0.7^ig/g 3.6+2.3^ig/g 
N=5 
Intratumoural HpD lOmg 4.7±3.2|ag/g 1.4±0.4^g/g � 




*means are given 士 standard deviation ；•： 
i!.. 
! • ' 
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Fig 5. Histological appearence of cryostat section of glioblastoma multiforme 
(case 5). Tumour centre consists of poorly differentiated pleomorphic glial cells. 
Tumour necrosis can also be seen (arrowed). (Intravenous administration group) 
(H&E x250) 
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Fig 6. Fluorescence microscopy of corresponding area in fig 5 shows lack of 
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I Fig 7. Histological appearance of tumour blood vessel in BAT region (case 2) 
I (intravenous administration group) {H&E x160) 
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Fig 8. Fluorescence photograph shows corresponding tissue section of fig 7. 
Note more intense fluorescence at the surrounding perivascular stroma 
(Intravenous administration group) (x160) 
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Fig 9. Histological appearance of BAT region of anaplastic astrocytoma with 
tumour blood vessel (case 3) (arrowed) (Intravenous administration group) {H&E 
x160) 
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Fig 10. Fluorescence photograph of corresponding region of fig 9 shows 
fluorescence distributed throughout the stroma and around of arterioles. 
(Intravenous administration group) ( x160) 
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Fig 11 • Cryostat section of central region of high grade oligodendroglioma (case 
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Fig 12. Corresponding fluorescence photograph of area in fig 11 shows bright 
and patchy distribution of fluorescence in tumour centre. ( x160) 
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Fig 13. Cryostat section of infiltrated tumour cell in BAT region (case 8). 
(lntratumoral injection group) { H&E x1000) 
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Fig 14. Corresponding fluorescence microscopy of fig 13 shows fluorescence 
located inside the cytoplasm of tumour cells but not the nucleus (arrow), 





Fig 1 5. CLSM shows fluorescence localized in cytoplasm at BAT region after 







CHAPTER 4. DISCUSSION 
At present, there is no satisfactory treatment for malignant cerebral glioma. Most 
treatments fail because of local recurrence of glioma, indicating that improving 
local control is necessary to increase the survival of patients. 
Photodynamic therapy (PDT) with haematoporphyrin derivative (HpD) has been 
H 
investigated as an adjuvant treatment for recurrent and newly diagnosed »; 
s' 
malignant glioma ( Perria et al. 1980; Laws et al. 1981; McCulloch et al. 1984). 
Since the first clinical trial of PDT in human glioma by Perria et al. (1980), more 
than 270 cases with intracranial neoplasms have been treated with PDT using a 
variety of treatment protocols (Origitano & Reichman 1993). Despite causing 
'、 
cytotoxic effects on tumour tissue, none of these studies has convincingly j 
'\ 
shown that HpD phototherapy can increase the survival time of patients. 
: |丨丨 
‘ fi '!•/ ( 
Evaluation of tumour response to PDT is difficult. In these clinical studies, ^ 
extensive surgical resection was usually undertaken, and in some cases followed 
by radiotherapy (Kaye, Morstyn & Brownbill 1987; Kostron et al. 1987). 
Treatment parameters of PDT were variable (Noske, Wolbers & Sterenborg 
1991). Usually there is no information available about the HpD concentration in 
tumour before photoillumination, which is an important factor in evaluating 











It is critical to monitor the uptake and distribution of photosensitizer within the 
tumour, because the efficacy and side effects of treatment depend on the drug 
level within the tumour. If drug uptake is absent or low, photoactivation cannot 
occur and the effects of treatment are minimal. 
The aim of this study was to evaluate the uptake and distribution of HpD in 
tumour and BAT region by different administration routes, in order to develop a 
H 
useful predictor of the efficacy of PDT before photoillumination. (! 
I y 
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1 .Quantifying HpD level 
A variety of methods have been used to quantify HpD uptake. These techniques 
include the use of radiolabeled HpD (Little et al. 1984), computer-enhanced 
optical digitometer (Kaye, Morstyn & Ashcroft 1985), fluorescence microscopy 
(Boggan et al. 1984; Wharen, Anderson & Laws 1983). However, these 
methods have limitations, since the HpD level may have been affected by 
rti 
incomplete HpD extraction and quenching of fluorescence signal. The quenching ； 
I 
'» 
could be due to aggregation of the sensitizer molecules or to the presence of 





The assay used in this study is based on a procedure developed by Kessel and 
I 
Cheng (1985). Hill et al. (1990) found this method reliable. It resulted in 
complete extraction of the sensitizer from tissue, and haemoglobin did not | 
enhance or quench the fluorescence, providing the absorbance of the assay j 
mixture was kept below a maximum value of 0.15 absorbance unit at 400nm. J 
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2. Quantifying HpD in the intravenous administration group 
In the present study, the mean HpD level in the BAT is higher than that in the 
tumour centre (3.6 i2.3 j ig/g vs 2.0±0.7Kg/g), but there is no significant 
difference (p>0.05) . This finding of a higher level of HpD in the BAT region is 
consistent with Hill's results (1990). In that study, the HpD uptake into the BAT 
was greater than the uptake into the tumour bulk in seven of eight cases in 
n 
which BAT tissue was excised, and in one other case the BAT value was 
» 
approximately 80% of the tumour value. Powers et ai. (1991) found the mean 
concentration of Photofrin II, a more purified form of haematoporphyria 
derivative, to be 8.5ng/mg in the BAT of recurrent malignant brain tumours, a 
level that is quite high and clearly capable of photosensitization. However, the 
1 
standard deviation in BAT region was 3.2, larger than that in tumour centre, ;j 
1 
which may reflect the variable permeability in BAT region. j 
. ; j 
I 
BAT is particularly important and widely studied because: (1) it may constitute ^ 
more than 10% of the total tumour volume (Groothuis et al. 1982). These 
malignant cells have a shorter cell cycle time than the tumour mass, and are 
probably responsible for recurrence after tumour excision. (2) The BAT region 
infiltrated by tumour cells is frequently fed by capillaries of normal brain, and 
may maintain the characteristics of the BBB. 
Since the BBB is the critical factor that limits the distribution of 
chemotherapeutic agent into tumour tissue, the characteristics of the BBB have 
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been widely studied, particularly the variation at the BAT region. BBB destruction 
has been observed in human and experimental brain tumour models. Using 
quantitative autoradiographic methods with a radiolabeled substance, the local 
blood to tissue transport constant (K) and blood f low (F) within a variety of brain 
tumour models can be measured (Yamada et al. 1982; Molnar et aL 1983). The 
transfer rate constant measured in experimental RT-9 brain tumour using ^^C -
alpha aminoisobutyric acid (^^C AIB) varied from tumour to tumour as well as 
ni 
within individual tumours. The K value in large tumours was significantly greater j 
！ 
• 
than that in small tumours. However, even the capillaries of large tumours were 
not completely permeable to AIB. The BAT also had higher K values, particularly 
around the large tumour. These results indicated that the BBB at the BAT region 




In addition, HpD level at the BAT region may also relate to regional blood f low. 
Regional blood flow within CNS tumours has been shown to be variable between 
I t 
different types of brain tumour and also within the same brain tumour. The mean " 
value of tumour blood flow may vary from zero, to values in exess of normal 
brain. The presence of higher proliferative areas, often within the periphery of a 
tumour might be expected to cause a high blood flow, whereas in regions of 
necrosis this would be expected to be low, and cysts would be associated with 
virtually no blood flow at all. (Yamada et al.1982; Molnar et al. 1983) 
However, other studies showed that the tumour centre usually had higher 




marked increase in capillary permeability was evident when the tumour become 
larger and central necrosis occurred. In tissue adjacent to large tumour, BBB 
permeability was about 3.5 times greater than that of normal brain tissue, but 
was about one-half to one-fifth of that in the viable part of large tumours. These 
studies demonstrated a considerable variability in regional vascular permeability. 
In this study, the low HpD level in the tumour centre may be due to lower blood 







In the present study, the HpD level varied from case to case. One case of 
I I 
anaplastic astrocytoma had a low HpD level at the tumour centre and BAT, 1.2 
and 0.8^ig/g respectively. This may be due to heterogeneity of tumour capillaries. 
Some capillaries are highly permeable, whereas others maintain characteristics of '| 
• I 
\ 
the normal BBB. The regional variations in the tumour capillaries lead to 丨 
I 
inadequate and non-uniform intratumoural distribution of photosensitizer. This 
can be observed in experimental animal models (Boggan et al. 1985). In an 
！ 
intracerebral 9L tumour assessed by digital video fluorescence microscopy after '• 
intravenous administration, the distributuon of HpD was limited and 
inhomogeneous. 
Further investigation using single photo emission computed tomography scans 
(SPECT) (Origitano et al. 1993), indicate that the photosensitizer uptake can vary 
from patient to patient even when the histological findings of the tumour are 
similar. Uptake of the photosensitizer seems to be affected by both the 




The finding of high level HpD in the BAT region in this study is a promising 
result. Since the level of HpD in tumour is the primary factor in determining the 
extent of tumour cell kill, with adequate light delivery, PDT can be expected to 
cause more tumour tissue destruction. However, the variation of HpD in BAT 
region was more prominent, so in order to achieve higher efficacy of PDT, it may 
be valuable to measure the HpD level before photoillumination. 
•li 1 ； 
i' 
1 
Recently, PDT was carried out with multiple stereotactically implanted optical 
I 
‘ I 
laser fibers (Origitano & Reichman 1993). Tumour tissue destruction could be 
expanded with some injury into the BAT, indicating that the BAT contained 
certain levels of HpD. However, PDT failed because of tumour regrowth at the j 
1 { 
margin of PDT damage and beyond. So the selective uptake of photosensitizer 
into the BAT region offers hope that with improved light delivery systems and 
:l 
improved light penetration into this region, PDT will be an effective adjuvant 
therapy in the treatment of gliomas. . 
62 
I 
3. Quantifying HpD in the intratumoural injection group 
Although studies have shown that preferential accumulation ot photosensitizer in 
tumour tissue is possible, limited and inhomogeneous distribution of HpD may be 
one of the reasons for reduced effectiveness of PDT. To achieve a higher 
concentration of HpD, Kostron et al. (1986) attempted direct intraneoplastic 
injection of photosensitizer into subcutaneous and intracranial tumours in the rat 
^ti 
glioma model. The results indicated that intraneoplastic injection was superior to ! 
4丨 
；I 
intraperitoneal injection for increasing tumour concentration of HpD, and 
produced a two to five fold increase in HpD content in the tumour relative to 




In a canine glioma model (Steichen, Dashmer & Martuza 1986), direct injection 
resulted in a higher HpD level in tumour tissue than intraperitoneal | 
administration, and lead to more efficient uptake of HpD, especially at the j 
tumour periphery. But the oedematous BAT contained HpD comparable to that 】 
of the normal ipsilateral and contralateral brain tissue. 
In an attempt to achieve higher concentrations of HpD in human glioma, but to 
avoid systemic toxicity of HpD, Kostron et al. (1987) first introduced direct 
intratumoural injection of HpD in human glioma. The procedure was to resect the 
bulk of tumour, followed by infiltration of the tumour bed with 1mg HpD per cm^ 
of the remaining tumour volume。Craniotomy was done 3 days later for 
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I 
intratumoural photoillumination. This resulted in a direct toxic effect on tumour 
cells and the vasculature remained intact. 
In our study, the stereotactic injection method modifies the approach of Kostron. 
All 5 patients had recurrent malignant glioma, and had previously been treated by 
surgery and radiotherapy. Initial stereotactic surgery was performed to inject HpD 
into the tumour. 24 hours later, routine craniotomy was carried out to debulk 
堪 




The mean HpD concentration in the tumour centre was 4.7±3.2p<g/g of tumour 
tissue, lower than 9.8^ig/g in Kostron's study (1987). This is due to the low 
‘ 
dose 10mg (2ml) of HpD injected into tumour tissue before operation. Since J 
most recurrent malignant glioma have raised intracranial pressure, direct 
1 
intratumoural injection HpD at a dose of 1mg/ cm^ developed in an animal model i 
before operation seems to be inappropriate in human glioma. Within the 
intratumoural injection group, there was a wide range of HpD concentration from ‘ 
2.6 to 10.3^ig/g tumour tissue. The variation may be caused by different sample 
positions within the tumour. 
Since most recurrence of tumour takes place at the periphery of the tumour, the 
aim of direct intratumoural injection is to circumvent the BBB, resulting in a 
higher HpD concentration. In this study, photosensitizer infiltrated into the BAT 
region from injection site, and HpD concentration in the BAT region is constant, 
but the level (1_4±0.4^ig/g) is less than the HpD level after intravenous injection 
64 
I 
(3.6i2.3pg/g). This result is compatable with other studies (Kostron et al. 1987), 
which show a concentration of 1.04i0.23j ig /g in the BAT region. These data 
showed that HpD reached the BAT region after intratumoural injection. Because 
the shape of tumour is irregular, the HpD level in the BAT region after tumoral 
centre injection may be low at this injected dosage. Higher injected dose may 
improve the diffusion of HpD to the tumour peripery. 
谢 
In this study, we injected HpD into the tumour centre via CT guided stereotactic 丨 
technique. This allowed more even distribution of photosensitizer within the 
tumour, and was a safe and reliable administration method. 
‘ 
In conclusion, direct intratumoural injection can achieve a significantly higher | 
level of HpD than the intravenous administration route. Also, intratumoural j 
injection can achieve a significantly higher level of HpD in tumour centre than 1 
BAT region. However, tumour cell infiltration may vary from region to region. j 
The regional heterogeneity of tumours have been studied by stereotactic biopsy. i 
In CT and MRI, contrast enhancement underestimated the extent of tumour 
infiltration. Tumour cells could be found beyond the area of low density, up to 2 
cm or more from the enhancing rim (Johnson, Hunt & Drayer 1989; Kelly et al. 
1987). The growth patterns and shape of tumours are highly irregular. Using 
direct intratumoural injection, it may by difficult to acquire even distribution into 
every region of the BAT if the tumours are very large. 
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From the result of our study, in bulky tumours where surgical excision is 
favourable, and where post-resectioned PDT of the BAT is contemplated, 
intravenous HpD infusion is preferred because of a higher HpD concentration is 
the BAT region. In small deep-seated tumour, intratumoral injection provides a 
higher HpD concentration for interstitial PDT. HpD measurement of the tumour 
and BAT regions is essential in selecting patients with adequate HpD 
concentrations, 
雄 
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4, Fluorescence microscopic study of HpD distribution of malignant gliomas 
In the intravenous HpD injection group, microscopic observation showed that 
fluorescence was unequally distributed throughout the tumour tissue, and this 
was more intense at the periphery of the tumour blood vessels. On further 
comparison with parallel examination of H&E stained serial tissue section, 
fluorescence was also located in extracellular stroma, with the exception of 
农 
necrotic, cystic and haemorrhagic regions. Fluorescence could also be found in ！ 
11 i 
the cytoplasm of some tumour cells, but not all cells. j 
The finding that there was more HpD at the periphery of the tumour blood 
vessels was consistent with other studies. Carpenter et al. (1977) also showed ！ 
that after HpD injection, fluorescence distributed maximally in blood vessels 
surrounding the tumour, and vascular walls showed fluorescence independently | 
I 
The distribution of HpD is the important factor determining the efficacy of PDT. ‘ 
After HpD is injected into the blood stream, it spreads through the vascular 
space, is transported across microvascular walls, and through the neoplastic 
interstitial space. It then crosses the neoplastic cellular membrane to reach the 
intracellular site. However, only a small percentage of HpD in circulating blood 
could be observed by fluorescence microscopy in tissue sections. 
The mechanism of direct tumour cell ki" as compared to vascular mediated 




vessels are damaged initially, with the tumour subsequently undergoing 
ischaemic changes. Histological changes seen through the electron microscope, 
reveal that the subendothelial zone of the tumour capillaries was initially 
destroyed, with subsequent tumour cell death secondary to haemorrhage and 
vascular collapse (Nelson, Liaw & Berns 1987). Kostron et al. (1987) also found 
that the phototoxic effect of intravenous injection was mediated predominantly 
by coagulation of the vessel, whereas intratumoural injection of HpD is directed 
'A 
mainly against the tumour cell itself. The distribution of HpD at the periphery of 
j 
tumour blood vessels after intravenous administration of HpD in the study, j 
') 





However, the finding that fluorescence was unequally distributed throughout the 
！ 
tumour tissue, and was more intense in the surrounding blood vessels, with less | 
I 
fluorescence in the necrosis region, demonstrated a considerable variability in | 
regional vascular permeability and BBB destruction. This inadequate drug 要 
distribution may limit the effectiveness of PDT in the treatment of malignant 
brain tumour. These results are in close agreement with the argument that 
vascular effect was an important mechanism of phototoxic effect by parenteral 
route. Regional variations of HpD fluorescence have also been observed within 
9L gliosarcoma brain tumour models (Boggan et al. 1984). In these experimental 
tumours, only 33% to 44% of the tumour was fluorescent. One explanation is 
that the mean intercapillary distance is increased; this increases the distance that 
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I 
the drug must diffuse, and may also account for the irregular distribution pattern 
of fluorescence. 
The intracellular localization of HpD is important in regard to selective destruction 
of tumour cells. However, only some tumour cells take up the photosensitizer, 
indicating that intracellular photosensitization was not the only mechanism of 
tumour cell destruction. Similar results have been reported by other investigators 
M 
(Carpenter et al. 1977; Steichen, Dashner & Martuza 1986). All these studies \ 
！ i 
i 
emphasized that fluorescence can be seen within the cell cytoplasm but not 
• 
within the nuclei. Further study of the target of cytotoxic process after PDT | 
showed the damage site located at cell membrane (Belliner & Dougherty 1982), 
mitochondria (Berns, Dahlman & Johnson 1982; Gomer et al. 1988) and f 
lysosomes (Torinuki, Miura & Seiji 1980), even inside the nucleus= Mitochondria | 
may be major targets in the cytotoxic process induced by PDT in glioma. \ 
I 
Phototoxicity and damage to lysosomes, with subsequent release of lysosomal | 
enzyme contents would also cause tumour cell destruction. Peng et al. (1990) ' 
also found a large number of Photofrin 11, another sensitizer used in clinical trials, 
bound to the membrane of the tumour cell in addition to components of the 
vascular system and of the interstitial. This is probably related to the lipophilicity 
of this drug. 
In our study, intense fluorescence could be found around the vascular system 
and the interstitium. This suggests that a combination of interstitial vascular 
damage and direct tumour cell effects is probably the mechanism that caused 
69 
tumour toxicity of PDT in the case of intravenous administration of the 
sensitizers. 
In the present study, bright and patchy distribution of fluorescence can be 
observed at the injection site in the intratumoural HpD injection group. HpD 
uptake into cytoplasm can also be seen around the injection site. The high 
concentration of HpD in the tumour centre and intracellular uptake of HpD by 
iA 
tumour cells indicated that phototoxic effect by intratumoural injection is 
predominantly against the tumour cells themselves. 
I 
t' j ' 
Fluorescence can also be found in the BAT region, although the intensity of 
fluorescence was much less than in the tumour centre. This is consistent with i 
the results of quantitative HpD analysis. Although the level of HpD uptake in the I 
I 
BAT is less, intracellular localization of HpD can be observed. Intratumoural | 
I 
administration of HpD has also been investigated (Steichen, Dashmer & Martuza | 
1986) in a transplantable canine glioma model, an important finding being I 
photosensitization of the finger-like infiltrations of the tumour. 
The finding that HpD was taken up by tumour cells in the BAT is very important. 
It appears direct intratumoural injection circumvents the BBB, results in spreading 
of photosensitizer throughout tumour tissue, achieving intracellular uptake by 
some tumour cells in the BAT region. 
70 
However, only a small number of tumour cells in the BAT region could take up 
photosensitizers, possibly related to the injecton dose and HpD diffusion. 
Although the intraneoplastic injection was satisfactory in an animal model, it 
seems that in the first study of 7 cases of human glioma, the outcome had not 









5. Confocal laser scanning microscopy (CLSM) study of HpD localization in 
malignant gliomas 
Confocal laser scanning microscopy uses a microscope that can generate clear 
thin optical section images. Not only can one obtain such remarkable optical 
section fluorescence images in a matter of seconds, but xz-sections can also be 
captured and rapidly displayed on the monitors. A series of optical sections 
K 
(stored in the memory of the built-in or add-on digital image processor) can be | 1 
i 
converted into and displayed as a stereo-pair. It can obtain clear optical sections | 
] 
of the distribution of fluorescence in 2D planes of a fluorescent 3D specimen. | 
(' 
And a stack of optical sections is easily combined to reveal three-dimensional 
fluorescent marker distributions. ^ 1 j 
A previous study using 5-amino levulinic acid (ALA), a precursor to | 
i f 
protoporphyrin IX, was scanned with the CLSM and optical spectrometer (Trepte | 
i 
0 et al. 1994). A spectral recording of the protoporphyrin signal was very similar ^ 
in shape to the macroscopical spectrum. This indicates that reliable recordings of 
porphyrins in tissue are possible using confocal microscope. Furthermore, the 
selective tumour uptake of a boronated porphyrin (BOPP) was studied in CBA 
mice bearing an implanted intracerebral glioma. CLSM of glioma cells in vitro and 
vivo showed that BOPP was localized within cytoplasm and excluded from the 
nucleus of these cells. The subcellular localization was confirmed by density 
gradient ultracentrifugation after homogenization of mouse tumour biopsies. The 
result showed that these discrete sites of flurorescence are within the 
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mitochondria, wi th low levels in the cytoplasm, lysosomes and Glogi, (Hill et al. 
1992) 
In this study, the CLSM micrographs show that photosensitizer localized in the 
nest of glioma cells around the oedematous brain adjacent to tumour region, 
which are thought responsible for tumour recurrence. In the intravenous injection 
group, photosensitizer localized in cytoplasm but was excluded from the nucleus 
1 
at BAT region. In the intratumoural injection group, intracellular localization of 
i I 












The aim of this study is to answer the question of which administration method 
is more effective for delivery of the photosensitizer in tumour bulk and BAT 
region. Based on the results of this study, intravenous administration of HpD is 
the method of choice in malignant glioma where subtotal resection can be 
achieved and PDT is delivered to BAT region. Intratumoural injection is the 
method of choice in small deep-seated inoperable tumours, it may combine | 
I 
interstitial PDT to achieve maximal tumour cell destruction. To achieve better | 
？( 
results, the uptake and distribution of photosensitizer in tumour and BAT needs | 
r I' 
to be quantified before photoillumination. Photosensitizer administration methods ！ 
f 
and the mode of light activation should be tailored to meet individual patients as 丨 
i 
the location, size, and geometry of the tumour is variable. j 
I li i 
. ii 
, I 
The clinical application of PDT for the treatment of malignant glioma is still in | 
its infancy. Improvements in PDT depend on obtaining a better understanding of 
the uptake of photosensitizers, the interaction with light, and the resulting 
photosensitization process. New sensitizers have been developed, including 
mTHPC and AIS4Pc. They can absorb light at a wavelength that is maximal for 
tissue penetration. New laser light sources should be sourced to produce higher 
power output at the appropriate wavelengths. It is also important to choose the 
right combination of different parameters, such as the route of administration, 
the light dose, and the method of light delivery. A possibility for the future is 
inserting multiple optical fibres during stereotic surgery into deep-seated 
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tumours. Multiple interstitial fibre implantation expands treatment into the area 
of extended tumour volume, where normal brain tissue is infiltrated by the 
tumour. It should also monitor the adverse effect of PDT, and compare the 
outcome of treatment with other therapies. 
In the foreseeable future, the strategies for treating malignant gliomas should be 
aimed at using multiple adjuvant therapies to achieve the maximal reduction of 
1 
residual tumour cells, which cause tumour recurrence. The potential of PDT for | 
I 
treatment of malignant glioma has not yet been fully explored. It deserves a j 
]i： 
logical approach: a chosen photosensitizer with a known tissue distribution and { 
f' 
/1 













CHAPTER 5. SUMMARY 
Photodynamic therapy is being investigated as an adjuvant treatment for 
malignant glioma. It is based on the selective retention of a photosensitizer in 
tumour tissue, with subsequent exposure to an appropriate wavelength of light, 
which causes activation of sensitizer and selective destruction of tumour tissue. 
In the past few years, more than 270 patients with intracranial neoplasm have j 
been treated with PDT. All studies showed a cytotoxic effect on tumour tissue | 
'I ji 







Tumour response to PDT may be affected by many factors. Selective uptake and | 
i 
retention of HpD by tumour tissue is an important factor that affects the efficacy 
of PDT. The treatment parameters are variable, and there is no information 
available for the HpD concentration in tumour tissue before photoillumination. 
Therefore it is difficult to evaluate the clinical response. 
Non-uniform distribution of HpD after conventional intravenous injection has 
been shown in previous studies. In order to achieve higher HpD concentration in 
tumour tissue, direct intratumoural injection has been adopted in human glioma. 
However the distribution of HpD after direct intratumoural injection has not been 
evaluated. The aim of the present study is to investigate the HpD distribution in 
tumour and BAT region, with different administration methods—intravenous 
76 
injection and intratumoural injection. This includes HpD level measurement at 
different regions, and further study carried out by fluorescence microscope and 
confocal laser scanning microscope (CLSM). 
A total of ten patients entered this trial. Five cases received HpD via intravenous 
route, the others via intratumoural injection route. 24 hours later, the patients 
underwent craniotomy. The biopsy specimens at different regions were used to 
analyse the HpD level. 
丨 jf 
In the intravenous injection group, all cases showed selective uptake of HpD in | 
'I i' 
tumour tissue, but the level was variable. The mean HpD level was 2.CH:0.7jLtg/g I 
i j 
in the tumour bulk and 3.6±2.3jag/g in the BAT region. | 
！ i: 
I 
The HpD level in BAT was higher than that in the tumour bulk, but there was no 
significant difference ( p > 0 . 0 5 )• The finding of a high level of HpD in BAT is 
important, and may be due to destruction of BBB in BAT region and high blood 
flow in this highly proliferative area. 
In the intratumoural injection group, all five patients presented with recurrent 
malignant glioma. 2ml (lOmg) of HpD was injected into the tumour centre under 
the guidance of stereotactic technique 24 hours before the operation. 
Intratumoural injection achieved a much higher HpD concentration in tumour bulk 
than BAT (4.7t3.2^ig/g vs 1.4±0.4jLig/g, p<0.05) . This study showed that 
stereotactic intratumoural injection technique is a safe and reliable administration 
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method for HpD infiltration into the BAT region. Intratumoural injection is suitable 
for interstitial PDT, that is, implantation of laser fibres into the centre of the deep 
lesion, where direct tumour resection is difficult. However, the HpD level in the 
BAT region is lower than that in the intravenous group. This may be due to low 
injection dose, and the irregular shape of the tumour may also account for the 
variation of HpD level at the BAT region. 
HpD distribution in malignant brain tumours was also studied by fluorescence ‘ 
microscope. In the intravenous injection group, fluorescence was unequally | 
丨  
distributed throughout the tumour tissue, and was more intense at the periphery | 
1 
of the tumour blood vessels. Also, fluorescence was found in extracellular I 
I I 
stroma and cytoplasm of some tumour cells. In the direct intratumoural injection 
group, bright and patchy distribution of fluorescence could be seen at the central 
region. Also intracellular uptake of HpD could be observed in the BAT region. 
Furthermore, confocal laser scanning microscope (CLSM) confirms that the 
photosensitizer was localized intracellularly in BAT region in both groups of 
patients. 
In conclusion, the significance of the results is: 
(1) Intravenous administration of photosensitizer is the delivery method of choice 
in brain tumour where subtotal resection can be achieved and PDT is 
contemplated to BAT region, because of a higher HpD level at this region. 
78 
(2) Intratumoural injection is the delivery method of choice in small deep-seated 
tumour. It is safe, reliable, and suitable for interstitial PDT. 
(3) HpD measurement should be carried out in all cases where BAT is the site for 
PDT. 
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